Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Tax Provisions: 2009-2025

Historic Tax Provisions for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $99.3 million.

  • UNITED THERAPEUTICS's Tax Provisions rose 24.91% to $99.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.7 million, marking a year-over-year increase of 20.70%. This contributed to the annual value of $343.9 million for FY2024, which is 18.79% up from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Tax Provisions of $99.3 million as of Q3 2025, which was up 0.40% from $98.9 million recorded in Q2 2025.
  • Over the past 5 years, UNITED THERAPEUTICS's Tax Provisions peaked at $101.3 million during Q1 2025, and registered a low of $4.2 million during Q1 2021.
  • For the 3-year period, UNITED THERAPEUTICS's Tax Provisions averaged around $84.8 million, with its median value being $84.2 million (2023).
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Tax Provisions slumped by 87.61% in 2021, and later skyrocketed by 1,538.10% in 2022.
  • Over the past 5 years, UNITED THERAPEUTICS's Tax Provisions (Quarterly) stood at $28.3 million in 2021, then surged by 65.02% to $46.7 million in 2022, then soared by 67.67% to $78.3 million in 2023, then rose by 21.58% to $95.2 million in 2024, then increased by 24.91% to $99.3 million in 2025.
  • Its Tax Provisions was $99.3 million in Q3 2025, compared to $98.9 million in Q2 2025 and $101.3 million in Q1 2025.